Lurbinectedin is a chemotherapy drug used for the treatment of small cell lung cancer (SCLC) that has progressed despite previous treatments. According to the sources provided, it appears that lurbinectedin is not widely available for cancer treatment.

The drug patent for lurbinectedin is held by PharmaMar, a Spanish pharmaceutical company, and the patent is set to expire in 2038 [1]. This suggests that other companies will not be able to produce and distribute generic versions of the drug until the patent expires.

In addition, a study published in the Journal of Clinical Oncology in 2021 found that although lurbinectedin showed promising results in treating SCLC, the drug is not yet widely available [2]. The study authors noted that the drug is not yet approved by all regulatory agencies and is not yet covered by all insurance plans.

The official website for Zepzelca, the brand name for lurbinectedin, also states that the drug is only available through specialty pharmacies and that patients should speak with their healthcare provider or pharmacist for more information on how to access the drug [3].

In summary, based on the sources provided, it appears that lurbinectedin is not widely available for cancer treatment. The drug is still under patent by PharmaMar, not yet approved by all regulatory agencies, and only available through specialty pharmacies.

Sources:
[1] https://www.drugpatentwatch.com/p/tradename/LURBINECTEDIN
[2] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8165873/
[3] https://www.zepzelca.com/faq/